← Leaderboards
Arjun Deb
University Of California Los Angeles
$19,563,654
Attributed
$25,089,004
Total exposure
13
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,089,004 · 13
By mechanism
R01$24,256,398 · 11
R00$747,000 · 1
K99$85,606 · 1
Top collaborators
- Matteo Pellegrini6 shared
- Vaithilingaraja Arumugaswami2 shared
- Thomas G Graeber2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Edward M De Robertis$3,809,117
- Christine E Mona$762,391
- Evan Robert Abt$202,486
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsHeartTissuesMyocardiumCardiacMolecularFibroblastsMediatingPhysiologicalGeneticAffectMyocardial InfarctionMuscle CellsInfarctionNatural RegenerationCicatrixPlayRepairedFibrosisLoss Of FunctionAnimalsCardiac MyocytesDilatation - ActionExtracellular
Grant awards (42)
Role of macrophages in regulating cardiac muscle metabolism$771,750
R01 · FY2025 · HL · contact PI
Targeting a ectonucleotidase in the heart with a monoclonal antibody to prevent post-infarct heart failure$752,174
R01 · FY2025 · HL · contact PI
Adenine metabolism in cardiac repair$727,945
R01 · FY2025 · HL · contact PI
Adenine metabolism in cardiac repair$742,320
R01 · FY2024 · HL · contact PI
Targeting a ectonucleotidase in the heart with a monoclonal antibody to prevent post-infarct heart failure$737,132
R01 · FY2024 · HL · contact PI
Role of GPNMB in cardiac remodeling$666,493
R01 · FY2024 · HL · contact PI
Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicity$2,378,661
R01 · FY2023 · DK · contact PI
Targeting a ectonucleotidase in the heart with a monoclonal antibody to prevent post-infarct heart failure$749,786
R01 · FY2023 · HL · contact PI
Role of GPNMB in cardiac remodeling$687,953
R01 · FY2023 · HL · contact PI
Targeting cardiac fibroblast-myocyte cross talk to enhance heart function after cardiac injury$546,000
R01 · FY2023 · HL · contact PI
Role of collagen heterogeneity in remodeling of acute and chronic heart scars$507,000
R01 · FY2023 · HL · contact PI
Identifying therapeutic strategies for the multisystem genetic disorder Pseudoxanthoma Elasticum$343,200
R01 · FY2023 · AR · contact PI
Role of GPNMB in cardiac remodeling$695,652
R01 · FY2022 · HL · contact PI
Targeting cardiac fibroblast-myocyte cross talk to enhance heart function after cardiac injury$546,000
R01 · FY2022 · HL · contact PI
Role of collagen heterogeneity in remodeling of acute and chronic heart scars$507,000
R01 · FY2022 · HL · contact PI
Identifying therapeutic strategies for the multisystem genetic disorder Pseudoxanthoma Elasticum$339,768
R01 · FY2022 · AR · contact PI
Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicity$3,636,473
R01 · FY2021 · DK · contact PI
Role of GPNMB in cardiac remodeling$702,950
R01 · FY2021 · HL · contact PI
Targeting cardiac fibroblast-myocyte cross talk to enhance heart function after cardiac injury$546,000
R01 · FY2021 · HL · contact PI
Role of collagen heterogeneity in remodeling of acute and chronic heart scars$507,000
R01 · FY2021 · HL · contact PI
Identifying therapeutic strategies for the multisystem genetic disorder Pseudoxanthoma Elasticum$332,904
R01 · FY2021 · AR · contact PI
Targeting cardiac fibroblast-myocyte cross talk to enhance heart function after cardiac injury$546,000
R01 · FY2020 · HL · contact PI
Role of ABCC6 in cardivascular calcification$516,873
R01 · FY2020 · HL · contact PI
Role of collagen heterogeneity in remodeling of acute and chronic heart scars$507,000
R01 · FY2020 · HL · contact PI
Identifying therapeutic strategies for the multisystem genetic disorder Pseudoxanthoma Elasticum$343,200
R01 · FY2020 · AR · contact PI
Role of ABCC6 in cardivascular calcification$516,873
R01 · FY2019 · HL · contact PI
Role of ABCC6 in cardivascular calcification$516,873
R01 · FY2018 · HL · contact PI
Role of mesenchymal-endothelial-transition in cardiac hypertrophy$385,000
R01 · FY2018 · HL · contact PI
Role of ABCC6 in cardivascular calcification$516,873
R01 · FY2017 · HL · contact PI
Role of mesenchymal-endothelial-transition in cardiac hypertrophy$385,000
R01 · FY2017 · HL · contact PI
Role of mesenchymal-endothelial-transition in cardiac hypertrophy$385,000
R01 · FY2016 · HL · contact PI
Role of mesenchymal-endothelial-transition in cardiac hypertrophy$385,000
R01 · FY2015 · HL · contact PI
Role of Wnts in Cardiac Repair$373,527
R01 · FY2014 · HL · contact PI
Role of Wnts in Cardiac Repair$253,310
R01 · FY2013 · HL · contact PI
Role of Wnts in Cardiac Repair$95,408
R01 · FY2013 · HL · contact PI
Role of Wnts in Cardiac Repair$366,300
R01 · FY2012 · HL · contact PI
Role of Wnts in Cardiac Repair$370,000
R01 · FY2011 · HL · contact PI
Role of Wnts in Cardiac Repair$370,000
R01 · FY2010 · HL · contact PI
Role of SFRP2 in cardiac regeneration$249,000
R00 · FY2010 · HL · contact PI
Role of SFRP2 in cardiac regeneration$249,000
R00 · FY2009 · HL · contact PI
Role of SFRP2 in cardiac regeneration$249,000
R00 · FY2008 · HL · contact PI
Role of Sfrp2 in Cardiac Regeneration$85,606
K99 · FY2007 · HL · contact PI